Spoken Alpha
Denali Therapeutics Inc.
Denali Therapeutics develops biotherapeutics designed to cross the blood-brain barrier and deliver medicines to the brain and body for treating neurodegenerative diseases, lysosomal storage disorders, and other serious conditions.
Denali Therapeutics Inc is a Healthcare company operating in Biotechnology with a $3.21B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for DNLI.
$ curl https://api.spokenalpha.com/v1/companies/DNLIFAQ
Spoken Alpha indexes DNLI's earnings call transcripts at https://spokenalpha.com/companies/DNLI. Each call links to attributed speakers and parsed analyst Q&A. Denali Therapeutics Inc.'s own investor relations page is at https://investors.denalitherapeutics.com/.
Denali Therapeutics Inc. (DNLI) held its most recent earnings call on 2026-11-03, covering fiscal Q3 2026.
Denali Therapeutics Inc. (DNLI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.67 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.68 | $-0.72 | +5.6% | $3.6M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.69 | $-0.71 | +2.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.73 | $-0.75 | +2.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.74 | $-0.76 | +2.6% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.72 | $-0.74 | +2.7% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $-0.78 | $-0.70 | -11.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $-0.67 | $-0.85 | +20.8% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.63 | $-0.63 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.59 | $-0.69 | +14.5% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.78 | $-0.66 | -18.2% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $-0.86 | $-0.80 | -7.5% | $-305.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.72 | $-0.79 | +8.9% | $1.3M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $1.30 | $-0.63 | +100.0% | $294.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-07 | $-0.80 | $-0.70 | -14.3% | $35.1M | — | — | EODHD |
| Q4 FY2022 | 2023-02-26 | $-0.75 | $-0.79 | +5.1% | $10.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.84 | $-0.79 | -6.3% | $3.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-07 | $-0.48 | $-0.55 | +12.7% | $52.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.53 | $-0.45 | -17.8% | $42.1M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.62 | $-0.41 | -51.2% | $12.5M | — | — | EODHD |
Source: EODHD. DNLI reported actuals as published; sparse fields render as —.